FlandersBio offers an up-to-date life sciences database with detailed information about all FlandersBio members.
FlandersBio beschikt over een geüpdate life sciences databank met een gedetailleerd overzicht van alle FlandersBio-ledenbedrijven.
Oxyrane develops improved therapeutic glycoproteins in the field of lysosomal storage disease products and antibodies using a glyco-engineered yeast production host and proprietary, purpose-built development tools.
Oxyrane develops therapeutic proteins and antibodies where the precise control of glycan content and structure is critical to efficacy. Oxyrane further enhances antibody products through the use of its proprietary engineering platform based on cell surface display technology and its engineered expression host.
In addition to developing an enhanced follow-on therapeutic, Oxyrane is leading a large antibody platform development project involving the UK National Biomanufacturing Centre operator and Cambridge University. As a result of this work, Oxyrane will have one of the most comprehensive and versatile platforms for the development, optimisation, and production of monoclonal antibodies.
Having developed distintcive, purpose-built expression tools, Oxyrane is now looking for strategic collaborations to fully exploit the full manufacturing potential of its platform.
Potential applications include:
Oxyrane has collaborations with groups based at the Flanders Institute for Biotechnology (VIB), L‘ Institut National de Recherche Agronomique (INRA), The University of Manchester, and Cambridge University. Oxyrane has worked closely with UK “Centres of Excellence” such as the Centre of Excellence for Biocatalysis, Biotransformations. and Biocatalytic Manufacture; the Centre for Process Innovation; and National Biomanufacturing Centre operator Eden Biodesign.